A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in N
A phase 3 trial of Glumetinib run by Shanghai JMT-Bio Inc. in non-small-cell lung cancer and small-cell lung cancer, now recruiting.
Overview
A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs is a phase 3 interventional study registered as NCT06829459 by Shanghai JMT-Bio Inc., with 350 participants planned, started 2025-04-03. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialPhase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）
Shares CSPC Pharmaceutical Group, Non-small-cell lung cancer.
- TrialA Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations
Shares CSPC Pharmaceutical Group, Non-small-cell lung cancer.
- TreatmentJMT101
Shares CSPC Pharmaceutical Group, Non-small-cell lung cancer.
- TreatmentSYS6010
Shares CSPC Pharmaceutical Group, Non-small-cell lung cancer.